MNMD trades 53.3% above Wall Street's consensus target of $20.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MNMD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Mind Medicine (MindMed) Inc. (MNMD) has a Wall Street consensus price target of $20.00, based on estimates from 1 covering analysts. With the stock currently trading at $42.79, this represents a potential downside of -53.3%. The company has a market capitalization of $3.23B.
Analyst price targets range from a low of $14.00 to a high of $28.00, representing a 70% spread in expectations. The median target of $20.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MNMD trades at a trailing P/E of -20.8x. Analysts expect EPS to grow -38.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CMPSCOMPASS Pathways plc | $1.9B | $13.75 | $18.63 | +35.5% | Buy | — | 15 |
 ATAIAtai Beckley Inc. | $2.7B | $7.35 | $7.69 | +4.6% | Hold | — | 8 |
 CYBNCybin Inc. | $304M | $6.09 | — | — | Buy | — | 4 |
 MGRXMangoceuticals, Inc. | $8M | $0.46 | — | — | — | — | — |
 SILOSilo Pharma, Inc. | $2M | $1.77 | — | — | — | — | — |
 LWAYLifeway Foods, Inc. | $341M | $22.31 | $32.00 | +43.4% | Buy | 42.9x | 7 |
 ENVBEnveric Biosciences, Inc. | $934324 | $1.56 | — | — | — | — | — |
 JAZZJazz Pharmaceuticals plc | $14.8B | $234.88 | $289.50 | +23.3% | Buy | 9.4x | 48 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 AXSMAxsome Therapeutics, Inc. | $10.0B | $193.45 | $282.53 | +46.0% | Buy | — | 26 |
Quick answers to the most common questions about buying MNMD stock.
MNMD's consensus price target is $20, -53.3% below the current price of $42.79. The 1 analysts tracking MNMD see downside risk at present valuations.
MNMD has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $20 implies -53.3% downside from current levels.
MNMD's current price is $42.79 with a consensus target of $20 (-53.3% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $28 for MNMD, while the most conservative target is $14. The consensus of $20 represents the median expectation. These targets typically reflect 12-month expectations.
MNMD is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MNMD stock forecast based on 1 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $14 (bear case) to $28 (bull case). The median consensus rating is "Buy".
Analysts are cautious on MNMD, with 0 Sell ratings and a price target of $20 (-53.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MNMD analyst price targets range from $14 to $28, a 70% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.